李氏大藥廠(00950.HK)抗精神病吸入劑關鍵試驗於中國入組首名患者
李氏大藥廠(00950.HK)公布,於今年4月29日,全資附屬李氏香港用於吸入系統的Staccato洛沙平(Adasuve)的關鍵試驗於中國入組首名患者。Adasuve是第一種亦是唯一一種用於急性治療成人精神分裂症或雙相情感障礙I型相關激動的口服洛沙平吸入粉霧劑。
該項研究正在內地19個試驗點進行,預計將入組約150名患者。患者入組預期將於今年下半年完成,而新藥申請預期將於明年下半年提交。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.